Vitiligo - Market Insights, Epidemiology and Market Forecast-2027



Albany, NY -- (SBWire) -- 09/27/2018 --DelveInsight has announced the addition of the  "Vitiligo - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines to their offering.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Vitiligo from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.Vitiligo is a long-term skin condition characterized by patches of the skin losing their pigment. The patches of skin affected become white and usually have sharp margins. The hair from the skin may also become white. The inside of the mouth and nose may also be involved. Typically both sides of the body are affected. Often the patches begin on areas of skin that are exposed to the sun. It is more noticeable in people with dark skin. Vitiligo may result in psychological stress and those affected may be stigmatized.

The Vitiligo epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. The disease Epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Prevalent population, Sex specific cases, Diagnosed Cases, Type Specific Diagnosed cases (segmental, non-segmental and unclassified) and Age Specific cases] scenario of Vitiligo in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to DelveInsight, the total prevalent population of Vitiligo was found to be 61,36,840, in the year 2016 and the total market size of Vitiligo in 7MM was found to be US878.5 million in 2016.

Geography Covered

1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Vitiligo Drug Companies

1. Incyte Corporation
2. Clinuvel Pharmaceutical
3. Aclaris Therapeutics
4. Celgene
And many others

Drugs covered

1. INCB018424
2. Scenesse
3. ATI-50002
4. Apremilast
And many others

Request for sample pages :,-Epidemiology-and-Market-Forecast-2027

Report Scope

1. The report covers detailed overview of Vitiligo explaining its causes, symptoms,
classification, pathophysiology, diagnosis and treatment patterns
2. The report provides the insight about the historical and forecasted patient pool of
Vitiligo in 7 major markets covering the United States, EU5 (Germany, Spain, France,
Italy, UK) & Japan
3. The Report assesses the disease risk and burden and highlights the unmet needs of the
4. The Report helps to recognize the growth opportunities in the 7MM with respect to
the patient population
5. The report provides the segmentation of the disease epidemiology by type i.e., Non-
segmental, segmental and unclassified vitiligo, age and sex specific cases in 7MM.

For more information about this report visit :,-Epidemiology-and-Market-Forecast-2027

Media Relations Contact

Ankit Nigam

View this press release online at: